Categories
Blood Cancer

BELINDA: Tisagenlecleucel in B-cell NHL [Video]

Michael Bishop, MD, University of Chicago, Chicago, IL, discusses results from the Phase III BELINDA trial (NCT03570892), which assessed tisagenlecleucel (tisa-cel), a chimeric antigen receptor (CAR) T-cell therapy, in patients with aggressive B-cell non-Hodgkin lymphoma. The primary endpoint, which was event-free survival, was not met, and tisa-cel was not superior to the current standard of care. Dr Bishop highlights the time taken for the therapy to be administered, bridging therapy, and the dosage of lymphodepleting chemotherapy to be factors affecting the trial results. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

The role of CAR-T therapy in hematologic malignancies [Video]

Michael Bishop, MD, University of Chicago, Chicago, IL, describes advances in chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. Data from the JULIET (NCT02445248), TRANSFORM (NCT03575351), BELINDA (NCT03570892), ZUMA-1 (NCT02348216), and ZUMA-7 (NCT03391466) trials have demonstrated CAR T-cell therapy as a promising frontline therapy in non-Hodgkin lymphoma. Dr Bishop additionally highlights updates in multiple myeloma and acute lymphoblastic leukemia (ALL), as well as strategies to manage CAR T-cell toxicity. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.